Login / Signup

iGlarLixi (insulin glargine 100 U/ml plus lixisenatide) is effective and well tolerated in people with uncontrolled type 2 diabetes regardless of age: A REALI pooled analysis of prospective real-world data.

Cristian GujaJános Tibor KisMartin HaluzíkMireille BonnemaireGregory BigotMathilde TournayNick FreemantleJochen Seufert
Published in: Diabetes, obesity & metabolism (2023)
iGlarLixi is effective and well tolerated in both younger and older people with uncontrolled T2D.
Keyphrases
  • type diabetes
  • glycemic control
  • electronic health record
  • insulin resistance
  • community dwelling
  • big data
  • physical activity
  • cardiovascular disease
  • middle aged
  • adipose tissue
  • metabolic syndrome
  • machine learning